Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RPL10P18 (ribosomal protein L10 pseudogene 18) is annotated as a pseudogene in the human genome, meaning it shares sequence similarity to the protein-coding RPL10 gene but does not encode a functional protein. Pseudogenes arise through gene duplication or retrotransposition, lacking the ability to produce biologically active products. RPL10P18 does not have documented biological functions, disease associations, or known drug interactions. It is not considered a receptor, enzyme, transporter, or recognized therapeutic target. The functional gene RPL10, by contrast, encodes a structural protein of the 60S ribosomal subunit essential for ribosome biogenesis and function. However, RPL10P18 is not involved in these processes and is generally ignored in pharmacological or therapeutic research. There is no evidence supporting any role of RPL10P18 in cell signaling, disease, or drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L10 pseudogene 18 (RPL10P18).